Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Yukinari Kono Named as Chief of Baxter Japan
December 6, 2022
- PeptiDream, RayzeBio Pick 1st Peptide Radiopharmaceutical Candidate
December 6, 2022
- Keytruda Filed in Japan for Primary Mediastinal Large B-Cell Lymphoma
December 6, 2022
- Deloitte Proposal to Shed Number of Generics Aims to Spur Industry Consolidation
December 5, 2022
- Mochida Set to Market Lilly’s Ulcerative Colitis Drug Candidate in Japan
December 5, 2022
- 2 Cancer Meds in PIII, Genmab to Rev Up Rep Hiring to Build Sales Regime in Japan
December 2, 2022
- Twymeeg Tops GP Promotion Ranking for 3 Months Running in September: Intage
December 2, 2022
- Healios to Provide Universal Donor Cells to Sumitomo
December 2, 2022
- Mochida Obtains Japan Marketing Rights for Ferring’s Ulcerative Colitis Drug
December 2, 2022
- Taisho’s Nanozora, 1st Nanobody Agent in Japan, Now Available
December 2, 2022
- AstraZeneca Japan Set to Buttress Respiratory Business with Tezspire Debut
December 2, 2022
- Ultragenyx to Ramp Up Ultra-Orphan Drug Development, Bolster Hiring in Japan
December 1, 2022
- Moderna Inks Digital Transformation Pact with Japanese Health Tech
December 1, 2022
- Novartis Rolls Out Cosentyx 300 mg Pen in Japan
December 1, 2022
- HUYA Japan to Transfer Hiyasta Marketing Authorization to Meiji
December 1, 2022
- Eisai Says 2 Trial Deaths Not Attributed to Lecanemab, No Change in Submission Plan
December 1, 2022
- Aricept Label Now Modified for Lewy Body Dementia Indication: Eisai
November 30, 2022
- Shionogi Curbs Shipments of Xofluza 10 mg on Big Demand
November 30, 2022
- Parexel Poised to Upsize Japan Workforce by 10%-Plus as Opportunities Expand
November 30, 2022
- SanBio Links Arms with Keio University on Alzheimer’s Drug Research
November 30, 2022
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…